XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
SCHEDULE OF DISAGGREGATED REVENUE

For the three and six months ended June 30, 2024 and 2023, the Company had the following disaggregated revenue:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   %   2023   %   2024   %   2023   % 
Telehealth revenue  $20,519,165    41%  $21,915,088    61%  $41,784,029    44%  $41,760,142    61%
LifeMD PC subscription revenue   13,881,894    27%   436,040    1%   21,489,682    23%   793,789    1%
WorkSimpli revenue   13,229,536    26%   13,595,785    38%   26,532,398    28%   26,519,317    38%
Medifast collaboration revenue   3,031,250    6%   -    -%   5,000,000    5%   -    -%
Total net revenue  $50,661,845    100%  $35,946,913    100%  $94,806,109    100%  $69,073,248    100%
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY

The following table summarizes deferred revenue activities for the periods presented:

 

   2024   2023   2024   2023 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Beginning of period  $13,202,757   $5,895,545   $8,828,598   $5,547,506 
Additions   50,449,028    33,760,427    95,042,515    64,965,817 
Revenue recognized   (48,490,126)   (33,987,762)   (88,709,454)   (64,845,113)
End of period  $15,161,659   $5,668,210   $15,161,659   $5,668,210 
SUMMARY OF INVENTORY

As of June 30, 2024 and December 31, 2023, the Company’s inventory consisted of the following:

 

   June 30,   December 31, 
   2024   2023 
         
Finished goods  $1,022,027   $1,216,833 
Raw materials and packaging components   1,379,436    1,898,784 
Inventory reserve   (340,744)   (355,685)
Total inventory, net  $2,060,719   $2,759,932 
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price could be less than the average market price of the common shares:

 

   2024   2023   2024   2023 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
                 
Series B Preferred Stock   -    1,548,594    -    1,493,991 
RSUs and RSAs   2,279,750    2,788,000    2,296,125    2,341,438 
Stock options   1,527,000    3,463,753    1,843,375    3,667,003 
Warrants   1,743,730    4,827,380    2,068,419    4,827,380 
Convertible long-term debt   671,141    1,342,282    671,141    1,342,282 
Potentially dilutive securities   6,221,621    13,970,009    6,879,060    13,672,094